Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $27.77 is 13.58% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 28.27||$ 41.57|
|Low:||$ 27.23||$ 24.45|
Company Description (as filed with the SEC)
We are a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. Our goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. We are focused on inclisiran, an investigational agent which is potentially a first-in-class lipid-lowering drug, to reduce LDL-cholesterol, or LDL-C, which is commonly referred to as "bad" cholesterol, in patients with atherosclerotic cardiovascular disease, or ASCVD, or cardiovascular risk-equivalents. We believe that inclisiran possesses favorable attributes that competitive products do not possess, would satisfy unmet medical needs and has the potential to improve the economics of healthcare. We have the right to develop, manufacture and commercialize inclisiran under our collaboration agreement with Alnylam Pharmaceuticals, Inc., or Alnylam. ... More ...
Nasdaq Official Price
Oct. 17, 2018
Oct. 17, 2018